Home › Applications › Drug Quality Control

Application

Nanomedicine Analysis with FLA

See whether a drug is encapsulated, and how it is organized inside its nanocarrier, without labels.

Fluorescence Lifetime Analysis (FLA) uses the intrinsic fluorescence of drugs such as doxorubicin to probe their physical state inside nanoformulations, directly in solution.

Because lifetime reflects the local molecular environment rather than the amount of signal, FLA can tell free, crystalline and membrane-associated drug apart, and reveal differences between formulations and batches that intensity alone cannot show.

02 Solutions

FLIM LABS solutions for drug quality control

FLIM LABS components and software cover the full chain shown above: pulsed excitation, single-photon detection with TCSPC acquisition, and phasor analysis of the measured lifetimes, for compact measurements in solution.

Spectroscopy

FLIM LABS Spectroscopy

Discover

Acquisition

FLIM DAQ

Discover

Excitation

Pulsed Laser Diodes

Discover

03 Projects

Funded projects in nanomedicine analysis

FLASH

JUMP 2023 · Proof of Concept

FLASH: Fluorescence Lifetime Analysis for the Screening of Healthcare Nanoformulations, led by Francesco Cardarelli at Scuola Normale Superiore in collaboration with FLIM LABS, and funded by the JUMP 2023 Proof-of-Concept programme.

Starting from a patented screening protocol that reveals the physical state of the active ingredient in encapsulated drugs, such as antitumoral nanoformulations, the project develops a compact device for pharmaceutical companies: drugs are analysed in their own solvent, without labelling, in a few seconds.

U-SCREEN

FISA 2024

U-SCREEN, led by Francesco Cardarelli at Scuola Normale Superiore in collaboration with FLIM LABS as host institution, and funded with €4.6 million by the Italian Fund for Applied Sciences (FISA 2024) of the Ministry of University and Research.

Over five years, the project develops a bench-top optical reader that checks in seconds, and without labels, the quality and stability of the lipid nanoparticles that carry RNA- and DNA-based drugs.

enLIGHT

ERC Proof of Concept 2025

enLIGHT, led by Francesco Cardarelli at Scuola Normale Superiore and funded by a European Research Council (ERC) Proof of Concept Grant, building on his ERC Consolidator project CAPTUR3D.

The project develops a compact, easy-to-use optical device to assess the physical state, encapsulation efficiency and stability of nano-formulated antidiabetic drugs, such as insulin, GLP-1 analogues and baricitinib.

Get started

Bring label-free drug characterization to your lab

Tell us about your formulations and we will help you build the right fluorescence lifetime setup for your drug quality control.